OncoSec Medical To Present at 2014 DNA Vaccine Conference
Leading the Discussion in Tumor Targeted Immunotherapy
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives will present at the International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in San Diego, CA.
As a Chairman’s Cup Sponsor for the event, OncoSec will be prominently featured during the conference. Speakers will include Robert Pierce, M.D., Chief Medical Officer, Soldano Ferrone, M.D., Ph.D., Scientific Advisory Board member, Richard Heller, Ph.D., Scientific Advisory Board member, and Holbrook Kohrt, M.D., Ph.D., clinical investigator.
Many of the leading investigators in cancer immunotherapy will be attending to discuss the latest research in immune-modulating antibodies, engineered T cells, gene delivery methods and combination approaches in immunotherapy. This year, several presentations will touch upon electroporation and its significance as a safe and efficient means of non-viral gene delivery, and discuss its clinical potential as an immuno-oncology platform.
There will also be a spotlight on the emerging field of intratumoral immunotherapy. Dr. Pierce will lead this session of the conference with his presentation “Intralesional DNA Immunotherapy: Converting Anti-PD-1 Non-Responders to Responders”, as part of the “Tumor Targeting” track.
“We are excited to have Dr. Holbrook Kohrt presenting his work in a talk entitled Anti-CTLA-4 and CPG: Experience with Direct Lesion Therapy," reports Dr. Pierce. “He and his colleagues at Stanford have been on the forefront of intratumoral therapy and thanks in part to these efforts, investigators are beginning to realize the potential of intratumoral therapies to directly combat the immunosuppressive mechanisms deployed by tumors. We are witnessing the emergence of a new vision—one in which the optimal future immunotherapy will combine intratumoral and systemic approaches.”
Punit Dhillon, President and CEO, announced, “We are proud to be a Chairman’s Cup Sponsor for this event. Each year, ISDV’s annual DNA Vaccines conference has become larger and better attended by key thought leaders in the space, and this year is no different. Including OncoSec, several of the leading companies in developing electroporation technology for DNA vaccines and immunotherapy will be presenting and sharing data, and this year, OncoSec will lead the discussion in the importance of developing intratumoral immunotherapies using electroporation.”
About the International Society of DNA Vaccines
The International Society of DNA Vaccines is an organization created to facilitate the advancement of therapeutic and preventive DNA vaccines. The society is comprised of international scientists and researchers who have dedicated their careers to improving world health and the advancement of DNA vaccines and therapies.
About the 2014 DNA Vaccine Conference
DNA Vaccines 2014 is a scientific conference that offers major opportunities for leading researchers worldwide to gather together and report on the cutting-edge advances in research in the field of DNA vaccines, debate accomplishments, and reveal new directions for translational exploitation. Highlights include scientific plenary sessions, scientific poster presentations and the attendance and participation of internationally renowned scientists and researchers.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
OncoSec Medical Inc.
Veronica Vallejo, CFO
Source: OncoSec Medical Inc.
Released July 17, 2014